Randomized, Double-Blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of TTP488 in Patients with Mild Alzheimer’s Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine.
An Extension Study of ANAVEX2-73 in Patients with Mild to Moderate Alzheimer’s Disease.
A Phase III, multicentre, randomised, Double-Blind, placebo-controlled, parallel-group, efficacy and safety study of crenezumab in participants with Prodromal to mild Alzheimer’s disease. (Protocol: BN29553) Cread 2
Anti-Amaloid Treatment in Asymptomatic Alzheimer's Disease.
A Phase 3, double blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer’s disease.
A Phase II/III Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease.
A Phase III, multicentre, randomised, double blind, placebo-controlled, parallel-group, efficacy and safety study with open label extension of Chrenexumab in patients with prodromal-rodromal -to mild Alzheimer's disease
A Phase III, randomised, double blind, placebo-controlled, parallel-group multicentre efficacy and safety study of Gantenerumab in patients with mild Alzheimer’s disease.
Study title: Mutlicentre, randomised, double blind, placebo controlled, parallel group two year study to evaluate the effect of subcutaneous RO4909832 on cognitive and function in prodromal Alzheimer's Disease.
Clinical Study No. RVT-101-3002, A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Alzheimer’s Disease.